Clinical Practice and Survival Analysis of Third-Line Therapy in Patients with Metastatic Colorectal Cancer: A Single-Center Retrospective Study
In the real-world setting, fruquintinib combined with immunotherapy was associated with benefits in third-line treatment of patients with pMMR mCRC. Shorter metastasis-to-PD2 interval and elevated baseline CA19-9 levels at the start of third-line therapy were independent poor prognostic factors.
Authors
- Buqun Fan
- Q D Li (ORCID: https://orcid.org/0000-0001-7651-564X)
- Yujun Li
- Hang Hubert Yin (ORCID: https://orcid.org/0000-0002-9762-4818)
- Jiakui Li (ORCID: https://orcid.org/0000-0002-6065-6648)
- Xia Zhang (ORCID: https://orcid.org/0009-0005-1159-9631)
- Xu Cui (ORCID: https://orcid.org/0000-0001-8783-3862)
- Yan Dong (ORCID: https://orcid.org/0000-0002-0742-0169)
- Anqi Xie (ORCID: https://orcid.org/0000-0003-2561-4407)
- Bin Zhang
- Lu Ma
- Jinghua Sun
- Xuebing Zhang
- Bolun Jiang
Institutions
- Dalian Medical University (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Second Affiliated Hospital of Dalian Medical University (CN)
- The Third People's Hospital of Dalian City (CN)
- Traditional Chinese Medicine Hospital of Kunshan (CN)
- First Affiliated Hospital of Dalian Medical University (CN)
Publication Details
- Journal
- Cancer Management and Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2147/cmar.s551664
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00